Skip to main content
Caplight Logo









Eroica Dx

Eroica Dx

Private
BarcelonaHealthcare & Life Scienceshttps://bist.eu

Company Overview

Eroica Dx operates in Healthcare & Life Sciences and is based in Barcelona. It was founded in 2025.

Eroica Dx is a biotechnology company that develops rapid, point-of-care diagnostic devices based on nanophotonic biosensors to identify bacterial pathogens and antimicrobial resistance markers.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Precision Medicine, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware + Subscription, Hardware Sales

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Eroica Dx Comparables

Compare Eroica Dx with similar companies based on industry and business-model similarity.

Eroica Dx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Novus Diagnostics
87%
Deepull
85%
Bioherent
78%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Eroica Dx Funding Rounds

Historical fundraising activity

Funding history

No completed funding rounds are published for Eroica Dx. Book a demo to ask about coverage.

Book a demo

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Eduard Vallory

Director General (CEO)

Executive Team

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 19, 2026

    Monthly visitors increased 64% MoM.

  • Jan 6, 2026

    Monthly visitors increased 90% MoM.

Book a demo to see all signals

For institutional investors. Book with your work email.

Eroica Dx Filings

Explore SEC and related filing metadata, where available.

Eroica Dx filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Eroica Dx's valuation, stock price, and market status.

Is Eroica Dx a public or private company?

Eroica Dx is a private company.

What is the current stock price of Eroica Dx?

Eroica Dx is a private company, so its shares have no public market price. Caplight tracks Eroica Dx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Eroica Dx worth (valuation)?

Valuation information for Eroica Dx is not publicly available.

Can I buy Eroica Dx stock?

Eroica Dx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Eroica Dx's last funding round?

Funding round information for Eroica Dx is not publicly available.

Who are the main investors in Eroica Dx?

Investor information for Eroica Dx is not publicly disclosed.

Will Eroica Dx IPO soon?

No public IPO plans have been announced for Eroica Dx.

How can I track Eroica Dx secondary market activity?

Caplight tracks bids, offers, and trades in Eroica Dx's shares on secondary markets.

Firmographic Details

HeadquartersBarcelona
Employee Range31
Year Founded2025
Last Funding—

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?